In yesterday’s Wall Street session, CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded at $42.94, up 2.02% from the previous session.
CRSP stock price is now 15.87% away from the 50-day moving average and -0.80% away from the 200-day moving average. The market capitalization of the company currently stands at $3.71B.
With the price target enhanced from $60 to $99, Evercore ISI Upgraded its rating from In-line to Outperform for CRISPR Therapeutics AG (NASDAQ: CRSP). On February 12, 2025, TD Cowen Upgraded its previous ‘Sell’ rating to ‘Hold’ on the stock keeping its target price maintained at $35, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, Patel Naimish, Chief Medical Officer sold 3,932 shares of the company’s stock on May 29 ’25. The stock was sold for $141,316 at an average price of $35.94. Upon completion of the transaction, the Chief Medical Officer now directly owns 6,068 shares in the company, valued at $0.26 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 21 ’25, Chief Executive Officer Kulkarni Samarth sold 10,031 shares of the business’s stock. A total of $413,578 was realized by selling the stock at an average price of $41.23. This leaves the insider owning 195,085 shares of the company worth $8.38 million. A total of 4.14% of the company’s stock is owned by insiders.
During the past 12 months, CRISPR Therapeutics AG has had a low of $30.04 and a high of $67.88. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 15.64, and a quick ratio of 15.64. The net profit margin was -1023.64% and return on equity was -19.71% for CRSP.
